Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study

Guido Parodi, Renato Valenti, Benedetta Bellandi, Angela Migliorini, Rossella Marcucci, Vincenzo Comito, Nazario Carrabba, Alberto Santini, Gian Franco Gensini, Rosanna Abbate, David Antoniucci

Research output: Contribution to journalArticle

302 Citations (Scopus)

Abstract

Objectives: This study sought to compare the action of prasugrel and ticagrelor in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI). Background: It has been documented that prasugrel and ticagrelor are able to provide effective platelet inhibition 2 h after a loading dose (LD). However, the pharmacodynamic measurements after prasugrel and ticagrelor LD have been provided by assessing only healthy volunteers or subjects with stable coronary artery disease. Methods: Fifty patients with STEMI undergoing PPCI with bivalirudin monotherapy were randomized to receive 60 mg prasugrel LD (n = 25) or 180 mg ticagrelor LD (n = 25). Residual platelet reactivity was assessed by VerifyNow at baseline and 2, 4, 8, and 12 h after LD. Results: Platelet reactivity units (PRU) 2 h after the LD (study primary endpoint) were 217 (12 to 279) and 275 (88 to 305) in the prasugrel and ticagrelor groups, respectively (p = NS), satisfying pre-specified noninferiority criteria. High residual platelet reactivity (HRPR) (PRU ≥240) was found in 44% and 60% of patients (p = 0.258) at 2 h. The mean time to achieve a PRU

Original languageEnglish
Pages (from-to)1601-1606
Number of pages6
JournalJournal of the American College of Cardiology
Volume61
Issue number15
DOIs
Publication statusPublished - Apr 16 2013

Fingerprint

Platelet Aggregation Inhibitors
Blood Platelets
Pharmaceutical Preparations
Percutaneous Coronary Intervention
Healthy Volunteers
ST Elevation Myocardial Infarction
Prasugrel Hydrochloride
Ticagrelor
Coronary Artery Disease
Myocardial Infarction

Keywords

  • myocardial infarction
  • prasugrel
  • stent
  • ticagrelor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients : RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. / Parodi, Guido; Valenti, Renato; Bellandi, Benedetta; Migliorini, Angela; Marcucci, Rossella; Comito, Vincenzo; Carrabba, Nazario; Santini, Alberto; Gensini, Gian Franco; Abbate, Rosanna; Antoniucci, David.

In: Journal of the American College of Cardiology, Vol. 61, No. 15, 16.04.2013, p. 1601-1606.

Research output: Contribution to journalArticle

Parodi, G, Valenti, R, Bellandi, B, Migliorini, A, Marcucci, R, Comito, V, Carrabba, N, Santini, A, Gensini, GF, Abbate, R & Antoniucci, D 2013, 'Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study', Journal of the American College of Cardiology, vol. 61, no. 15, pp. 1601-1606. https://doi.org/10.1016/j.jacc.2013.01.024
Parodi, Guido ; Valenti, Renato ; Bellandi, Benedetta ; Migliorini, Angela ; Marcucci, Rossella ; Comito, Vincenzo ; Carrabba, Nazario ; Santini, Alberto ; Gensini, Gian Franco ; Abbate, Rosanna ; Antoniucci, David. / Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients : RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. In: Journal of the American College of Cardiology. 2013 ; Vol. 61, No. 15. pp. 1601-1606.
@article{cb842260d74a49e48cec5a512657e40f,
title = "Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study",
abstract = "Objectives: This study sought to compare the action of prasugrel and ticagrelor in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI). Background: It has been documented that prasugrel and ticagrelor are able to provide effective platelet inhibition 2 h after a loading dose (LD). However, the pharmacodynamic measurements after prasugrel and ticagrelor LD have been provided by assessing only healthy volunteers or subjects with stable coronary artery disease. Methods: Fifty patients with STEMI undergoing PPCI with bivalirudin monotherapy were randomized to receive 60 mg prasugrel LD (n = 25) or 180 mg ticagrelor LD (n = 25). Residual platelet reactivity was assessed by VerifyNow at baseline and 2, 4, 8, and 12 h after LD. Results: Platelet reactivity units (PRU) 2 h after the LD (study primary endpoint) were 217 (12 to 279) and 275 (88 to 305) in the prasugrel and ticagrelor groups, respectively (p = NS), satisfying pre-specified noninferiority criteria. High residual platelet reactivity (HRPR) (PRU ≥240) was found in 44{\%} and 60{\%} of patients (p = 0.258) at 2 h. The mean time to achieve a PRU",
keywords = "myocardial infarction, prasugrel, stent, ticagrelor",
author = "Guido Parodi and Renato Valenti and Benedetta Bellandi and Angela Migliorini and Rossella Marcucci and Vincenzo Comito and Nazario Carrabba and Alberto Santini and Gensini, {Gian Franco} and Rosanna Abbate and David Antoniucci",
year = "2013",
month = "4",
day = "16",
doi = "10.1016/j.jacc.2013.01.024",
language = "English",
volume = "61",
pages = "1601--1606",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "15",

}

TY - JOUR

T1 - Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients

T2 - RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study

AU - Parodi, Guido

AU - Valenti, Renato

AU - Bellandi, Benedetta

AU - Migliorini, Angela

AU - Marcucci, Rossella

AU - Comito, Vincenzo

AU - Carrabba, Nazario

AU - Santini, Alberto

AU - Gensini, Gian Franco

AU - Abbate, Rosanna

AU - Antoniucci, David

PY - 2013/4/16

Y1 - 2013/4/16

N2 - Objectives: This study sought to compare the action of prasugrel and ticagrelor in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI). Background: It has been documented that prasugrel and ticagrelor are able to provide effective platelet inhibition 2 h after a loading dose (LD). However, the pharmacodynamic measurements after prasugrel and ticagrelor LD have been provided by assessing only healthy volunteers or subjects with stable coronary artery disease. Methods: Fifty patients with STEMI undergoing PPCI with bivalirudin monotherapy were randomized to receive 60 mg prasugrel LD (n = 25) or 180 mg ticagrelor LD (n = 25). Residual platelet reactivity was assessed by VerifyNow at baseline and 2, 4, 8, and 12 h after LD. Results: Platelet reactivity units (PRU) 2 h after the LD (study primary endpoint) were 217 (12 to 279) and 275 (88 to 305) in the prasugrel and ticagrelor groups, respectively (p = NS), satisfying pre-specified noninferiority criteria. High residual platelet reactivity (HRPR) (PRU ≥240) was found in 44% and 60% of patients (p = 0.258) at 2 h. The mean time to achieve a PRU

AB - Objectives: This study sought to compare the action of prasugrel and ticagrelor in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI). Background: It has been documented that prasugrel and ticagrelor are able to provide effective platelet inhibition 2 h after a loading dose (LD). However, the pharmacodynamic measurements after prasugrel and ticagrelor LD have been provided by assessing only healthy volunteers or subjects with stable coronary artery disease. Methods: Fifty patients with STEMI undergoing PPCI with bivalirudin monotherapy were randomized to receive 60 mg prasugrel LD (n = 25) or 180 mg ticagrelor LD (n = 25). Residual platelet reactivity was assessed by VerifyNow at baseline and 2, 4, 8, and 12 h after LD. Results: Platelet reactivity units (PRU) 2 h after the LD (study primary endpoint) were 217 (12 to 279) and 275 (88 to 305) in the prasugrel and ticagrelor groups, respectively (p = NS), satisfying pre-specified noninferiority criteria. High residual platelet reactivity (HRPR) (PRU ≥240) was found in 44% and 60% of patients (p = 0.258) at 2 h. The mean time to achieve a PRU

KW - myocardial infarction

KW - prasugrel

KW - stent

KW - ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=84875997213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875997213&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2013.01.024

DO - 10.1016/j.jacc.2013.01.024

M3 - Article

C2 - 23500251

AN - SCOPUS:84875997213

VL - 61

SP - 1601

EP - 1606

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 15

ER -